Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: David Cathcart who wrote (716)	2/20/1998 1:41:00 PM
From: seminole	Read Replies (2) \| Respond to of 1826

David Good review of MGI 114. You have present the bottom line reasons for owning this drug through MOGN stock. Phase II trials and shrinking tumors will be the best early test. I believe those of you who do not believe should wait to purchase. Purchase the stock based upon success in the clinical trials not upon messages posted here. Why is this drug so good? Because the tumors act as little vacuum cleaners, they suck up the drug before it can damage other healthy cells and organs. I have a theory that this drug's toxicity level will be much lower for healthy patients than for patients with tumors. Why is this drug so good? Because its not really one drug. Yes, MOGN is testing the one lead compound MGI 114 but there other similar compounds (analogs) that work in the lab. Maybe and hopefully MGI 114 is the best drug from this class of compounds but maybe there is one better. MOGN has stable of interesting compounds all with slightly different toxicity and activity transport properties. Why is this drug so good? It never fails in the lab. It is always tested against other cancer drugs and it has never been beat. And when someone like the NCI starts spending a little money on research, we will find out more reasons why the drug is so good. richard